GB9625968D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB9625968D0
GB9625968D0 GB9625968A GB9625968A GB9625968D0 GB 9625968 D0 GB9625968 D0 GB 9625968D0 GB 9625968 A GB9625968 A GB 9625968A GB 9625968 A GB9625968 A GB 9625968A GB 9625968 D0 GB9625968 D0 GB 9625968D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9625968A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Equine Virology Research Foundation
Cambridge University Technical Services Ltd CUTS
Original Assignee
University of Glasgow
Equine Virology Research Foundation
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Equine Virology Research Foundation, Cambridge University Technical Services Ltd CUTS filed Critical University of Glasgow
Priority to GB9625968A priority Critical patent/GB9625968D0/en
Publication of GB9625968D0 publication Critical patent/GB9625968D0/en
Priority to JP52634398A priority patent/JP2002512504A/en
Priority to AU54018/98A priority patent/AU738684B2/en
Priority to CA 2274900 priority patent/CA2274900A1/en
Priority to EP19970947773 priority patent/EP0946714A1/en
Priority to PCT/GB1997/003327 priority patent/WO1998026049A1/en
Priority to HU0002374A priority patent/HUP0002374A3/en
Priority to US10/033,538 priority patent/US20020155131A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB9625968A 1996-12-13 1996-12-13 Vaccine Pending GB9625968D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB9625968A GB9625968D0 (en) 1996-12-13 1996-12-13 Vaccine
JP52634398A JP2002512504A (en) 1996-12-13 1997-12-10 Recombinant equine herpesvirus type 1 (EHV-1) containing a dysfunctional 71 gene region and its use as a vaccine
AU54018/98A AU738684B2 (en) 1996-12-13 1997-12-10 Recombinant equine herpesvirus type 1 (EHV-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine
CA 2274900 CA2274900A1 (en) 1996-12-13 1997-12-10 Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine
EP19970947773 EP0946714A1 (en) 1996-12-13 1997-12-10 Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine
PCT/GB1997/003327 WO1998026049A1 (en) 1996-12-13 1997-12-10 Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine
HU0002374A HUP0002374A3 (en) 1996-12-13 1997-12-10 Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine
US10/033,538 US20020155131A1 (en) 1996-12-13 2001-10-19 Recombinant equine herpesvirus type 1 (EHV-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9625968A GB9625968D0 (en) 1996-12-13 1996-12-13 Vaccine

Publications (1)

Publication Number Publication Date
GB9625968D0 true GB9625968D0 (en) 1997-01-29

Family

ID=10804436

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9625968A Pending GB9625968D0 (en) 1996-12-13 1996-12-13 Vaccine

Country Status (7)

Country Link
EP (1) EP0946714A1 (en)
JP (1) JP2002512504A (en)
AU (1) AU738684B2 (en)
CA (1) CA2274900A1 (en)
GB (1) GB9625968D0 (en)
HU (1) HUP0002374A3 (en)
WO (1) WO1998026049A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
AR040601A1 (en) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed GM NEGATIVE EHV MUTANTS WITHOUT HETEROLOGICAL ELEMENTS
GB2406644B (en) * 2002-07-26 2006-08-30 Animal Health Trust Viral marker
NZ700470A (en) * 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof

Also Published As

Publication number Publication date
JP2002512504A (en) 2002-04-23
AU5401898A (en) 1998-07-03
AU738684B2 (en) 2001-09-27
HUP0002374A2 (en) 2000-11-28
WO1998026049A1 (en) 1998-06-18
CA2274900A1 (en) 1998-06-18
HUP0002374A3 (en) 2001-12-28
EP0946714A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
HUP9904549A3 (en) Vaccines
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
PL341698A1 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
EP0958373A4 (en) Vaccines
PL331424A1 (en) Antipaludian vaccine composition
GB9623233D0 (en) Vaccine composition
ZA9711565B (en) Vaccine
GB9625968D0 (en) Vaccine
ZA982763B (en) Vaccines
ZA957482B (en) Vaccine
ZA973824B (en) Vaccines
GB9419969D0 (en) Vaccine
GB9625966D0 (en) Vaccine
GB9625967D0 (en) Vaccine
GB9604595D0 (en) Vaccines
GB9605229D0 (en) Vaccines
GB9626882D0 (en) Vaccines
GB9602617D0 (en) Vaccines
GB9614182D0 (en) Vaccines
GB9606032D0 (en) Vaccines
GB9604596D0 (en) Vaccines